Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lil | Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lilly ...

Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager (TCE) for prostate cancer. | Astellas is aiding Vir ...

Rome-based Angelini Pharma has inked a multi-year deal with Massachusetts biotech Quiver Bioscience that is designed to advance novel therapies for genetic epilepsies and could garner up to $120 ...

After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...

A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension (PAH) has missed its primary endpoint, triggering a 77% crash in the biotech’s share price. The company has paused ...

Gilead has struck a deal to buy Arcellx for $7.8 billion to take full control of a CAR-T cell therapy that is on the cusp of approval.

The FDA is flagging a high-risk issue with blood glucose monitors manufactured by Trividia Health that the company says is tied to 114 serious injuries and one death since the devices’ launch 12 years ...

MoonLake Immunotherapeutics has kicked off a year of readouts for its much-hyped inflammatory disease prospect with a ...

Demyelinating diseases, including multiple sclerosis (MS) and Charcot-Marie-Tooth (CMT) disease, present a substantial and ...

Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service (NHS) ...

Four years after he resigned as chief medical officer at Novartis in the wake of a restructuring at the Big Pharma, John Tsai ...

As Candel Therapeutics gears up for a planned U.S. approval push for its prostate cancer drug later this year, RTW ...